TNF signaling pathway |
110 |
42.9 |
80 |
80 |
5.09E-13 |
5.09E-13 |
1.62E-10 |
1.62E-10 |
Non-alcoholic fatty liver disease (NAFLD) |
149 |
58.1 |
99 |
99 |
7.23E-12 |
7.23E-12 |
1.15E-09 |
1.15E-09 |
Metabolic pathways |
1430 |
558 |
670 |
670 |
1.40E-11 |
1.40E-11 |
1.49E-09 |
1.49E-09 |
Herpes simplex infection |
492 |
192 |
261 |
261 |
4.63E-11 |
4.63E-11 |
3.68E-09 |
3.68E-09 |
Pancreatic cancer |
75 |
29.2 |
57 |
57 |
6.33E-11 |
6.33E-11 |
4.02E-09 |
4.02E-09 |
HTLV-I infection |
219 |
85.4 |
130 |
130 |
5.07E-10 |
5.07E-10 |
2.69E-08 |
2.69E-08 |
Hepatitis C |
155 |
60.4 |
98 |
98 |
6.30E-10 |
6.30E-10 |
2.86E-08 |
2.86E-08 |
Epstein-Barr virus infection |
201 |
78.4 |
120 |
120 |
1.46E-09 |
1.46E-09 |
5.80E-08 |
5.80E-08 |
Cell cycle |
124 |
48.3 |
81 |
81 |
2.06E-09 |
2.06E-09 |
7.28E-08 |
7.28E-08 |
Colorectal cancer |
86 |
33.5 |
60 |
60 |
6.08E-09 |
6.08E-09 |
1.93E-07 |
1.93E-07 |
DNA replication |
36 |
14 |
31 |
31 |
6.79E-09 |
6.79E-09 |
1.96E-07 |
1.96E-07 |
Hepatitis B |
163 |
63.5 |
98 |
98 |
2.87E-08 |
2.87E-08 |
7.60E-07 |
7.60E-07 |
Apoptosis |
136 |
53 |
84 |
84 |
5.10E-08 |
5.10E-08 |
1.25E-06 |
1.25E-06 |
Chronic myeloid leukemia |
76 |
29.6 |
52 |
52 |
1.73E-07 |
1.73E-07 |
3.92E-06 |
3.92E-06 |
Influenza A |
167 |
65.1 |
96 |
96 |
7.79E-07 |
7.79E-07 |
1.65E-05 |
1.65E-05 |
Huntington’s disease |
193 |
75.2 |
108 |
108 |
1.00E-06 |
1.00E-06 |
1.99E-05 |
1.99E-05 |
Small cell lung cancer |
93 |
36.3 |
59 |
59 |
1.40E-06 |
1.40E-06 |
2.54E-05 |
2.54E-05 |
Prostate cancer |
97 |
37.8 |
61 |
61 |
1.44E-06 |
1.44E-06 |
2.54E-05 |
2.54E-05 |
Parkinson’s disease |
142 |
55.4 |
83 |
83 |
1.72E-06 |
1.72E-06 |
2.87E-05 |
2.87E-05 |
AGE-RAGE signaling pathway in diabetic complications |
100 |
39 |
62 |
62 |
2.38E-06 |
2.38E-06 |
3.78E-05 |
3.78E-05 |
Endometrial cancer |
58 |
22.6 |
40 |
40 |
3.38E-06 |
3.38E-06 |
5.12E-05 |
5.12E-05 |
Non-small cell lung cancer |
66 |
25.7 |
44 |
44 |
4.53E-06 |
4.53E-06 |
6.55E-05 |
6.55E-05 |
Kaposi’s sarcoma-associated herpesvirus infection |
186 |
72.5 |
102 |
102 |
6.78E-06 |
6.78E-06 |
9.37E-05 |
9.37E-05 |
Measles |
138 |
53.8 |
79 |
79 |
9.06E-06 |
9.06E-06 |
0.000116 |
0.000116 |
Platinum drug resistance |
73 |
28.5 |
47 |
47 |
9.16E-06 |
9.16E-06 |
0.000116 |
0.000116 |
Alzheimer’s disease |
171 |
66.7 |
94 |
94 |
1.35E-05 |
1.35E-05 |
0.000166 |
0.000166 |
Endocrine resistance |
98 |
38.2 |
59 |
59 |
1.55E-05 |
1.55E-05 |
0.000182 |
0.000182 |
Pathways in cancer |
530 |
207 |
252 |
252 |
2.01E-05 |
2.01E-05 |
0.000229 |
0.000229 |
Glioma |
75 |
29.2 |
47 |
47 |
2.62E-05 |
2.62E-05 |
0.000287 |
0.000287 |
Valine, leucine and isoleucine degradation |
48 |
18.7 |
33 |
33 |
2.71E-05 |
2.71E-05 |
0.000288 |
0.000288 |
Tuberculosis |
179 |
69.8 |
96 |
96 |
4.15E-05 |
4.15E-05 |
0.000425 |
0.000425 |
Ubiquitin mediated proteolysis |
137 |
53.4 |
76 |
76 |
5.89E-05 |
5.89E-05 |
0.000585 |
0.000585 |
Oxidative phosphorylation |
133 |
51.8 |
74 |
74 |
6.44E-05 |
6.44E-05 |
0.00062 |
0.00062 |
Base excision repair |
33 |
12.9 |
24 |
24 |
8.52E-05 |
8.52E-05 |
0.000797 |
0.000797 |
Endocytosis |
244 |
95.1 |
124 |
124 |
9.11E-05 |
9.11E-05 |
0.000828 |
0.000828 |
Autophagy - animal |
128 |
49.9 |
71 |
71 |
0.000102 |
0.000102 |
0.000905 |
0.000905 |
p53 signaling pathway |
72 |
28.1 |
44 |
44 |
0.000112 |
0.000112 |
0.000963 |
0.000963 |
Glyoxylate and dicarboxylate metabolism |
30 |
11.7 |
22 |
22 |
0.000139 |
0.000139 |
0.00116 |
0.00116 |
Mismatch repair |
23 |
8.97 |
18 |
18 |
0.000143 |
0.000143 |
0.00117 |
0.00117 |
EGFR tyrosine kinase inhibitor resistance |
79 |
30.8 |
47 |
47 |
0.000167 |
0.000167 |
0.00132 |
0.00132 |
Neurotrophinsignaling pathway |
119 |
46.4 |
66 |
66 |
0.000178 |
0.000178 |
0.00132 |
0.00132 |
Legionellosis |
55 |
21.4 |
35 |
35 |
0.000179 |
0.000179 |
0.00132 |
0.00132 |
B cell receptor signaling pathway |
71 |
27.7 |
43 |
43 |
0.000179 |
0.000179 |
0.00132 |
0.00132 |
FoxOsignaling pathway |
132 |
51.5 |
72 |
72 |
0.000186 |
0.000186 |
0.00134 |
0.00134 |
NOD-like receptor signaling pathway |
178 |
69.4 |
93 |
93 |
0.000193 |
0.000193 |
0.00136 |
0.00136 |
Fluid shear stress and atherosclerosis |
139 |
54.2 |
75 |
75 |
0.000217 |
0.000217 |
0.0015 |
0.0015 |
Chagas disease (American trypanosomiasis) |
103 |
40.2 |
58 |
58 |
0.000252 |
0.000252 |
0.0017 |
0.0017 |
Progesterone-mediated oocyte maturation |
99 |
38.6 |
56 |
56 |
0.000273 |
0.000273 |
0.00181 |
0.00181 |
IL-17 signaling pathway |
93 |
36.3 |
53 |
53 |
0.000306 |
0.000306 |
0.00199 |
0.00199 |
ErbBsignaling pathway |
85 |
33.1 |
49 |
49 |
0.000354 |
0.000354 |
0.00225 |
0.00225 |
Protein processing in endoplasmic reticulum |
165 |
64.3 |
86 |
86 |
0.000368 |
0.000368 |
0.00229 |
0.00229 |
HIF-1 signaling pathway |
100 |
39 |
56 |
56 |
0.000387 |
0.000387 |
0.00237 |
0.00237 |
Mitophagy - animal |
65 |
25.3 |
39 |
39 |
0.000463 |
0.000463 |
0.00273 |
0.00273 |
Central carbon metabolism in cancer |
65 |
25.3 |
39 |
39 |
0.000463 |
0.000463 |
0.00273 |
0.00273 |
Carbon metabolism |
116 |
45.2 |
63 |
63 |
0.000535 |
0.000535 |
0.0031 |
0.0031 |
Pertussis |
76 |
29.6 |
44 |
44 |
0.000614 |
0.000614 |
0.00349 |
0.00349 |
Prolactin signaling pathway |
70 |
27.3 |
41 |
41 |
0.000673 |
0.000673 |
0.00376 |
0.00376 |
Osteoclast differentiation |
128 |
49.9 |
68 |
68 |
0.000745 |
0.000745 |
0.00408 |
0.00408 |
Toxoplasmosis |
113 |
44 |
61 |
61 |
0.000802 |
0.000802 |
0.00432 |
0.00432 |
mTORsignaling pathway |
153 |
59.6 |
79 |
79 |
0.000903 |
0.000903 |
0.00479 |
0.00479 |
Nucleotide excision repair |
47 |
18.3 |
29 |
29 |
0.00131 |
0.00131 |
0.00674 |
0.00674 |
Proteasome |
45 |
17.5 |
28 |
28 |
0.00131 |
0.00131 |
0.00674 |
0.00674 |
Melanoma |
72 |
28.1 |
41 |
41 |
0.00146 |
0.00146 |
0.00735 |
0.00735 |
NF-kappa B signaling pathway |
100 |
39 |
54 |
54 |
0.00155 |
0.00155 |
0.00769 |
0.00769 |
Epithelial cell signaling in Helicobacter pylori infection |
68 |
26.5 |
39 |
39 |
0.00157 |
0.00157 |
0.00769 |
0.00769 |
Acute myeloid leukemia |
66 |
25.7 |
38 |
38 |
0.00163 |
0.00163 |
0.00785 |
0.00785 |
Viral carcinogenesis |
201 |
78.4 |
99 |
99 |
0.00173 |
0.00173 |
0.00823 |
0.00823 |
Breast cancer |
147 |
57.3 |
75 |
75 |
0.00184 |
0.00184 |
0.00863 |
0.00863 |
Citrate cycle (TCA cycle) |
30 |
11.7 |
20 |
20 |
0.00195 |
0.00195 |
0.00897 |
0.00897 |
Vibrio cholerae infection |
50 |
19.5 |
30 |
30 |
0.00205 |
0.00205 |
0.00923 |
0.00923 |
Lysosome |
123 |
47.9 |
64 |
64 |
0.00209 |
0.00209 |
0.00923 |
0.00923 |
Notch signaling pathway |
48 |
18.7 |
29 |
29 |
0.00209 |
0.00209 |
0.00923 |
0.00923 |
Hippo signaling pathway |
154 |
60 |
77 |
77 |
0.00326 |
0.00326 |
0.0142 |
0.0142 |
Tight junction |
170 |
66.3 |
84 |
84 |
0.00333 |
0.00333 |
0.0143 |
0.0143 |
Bladder cancer |
41 |
16 |
25 |
25 |
0.00351 |
0.00351 |
0.0147 |
0.0147 |
Apoptosis - multiple species |
33 |
12.9 |
21 |
21 |
0.00354 |
0.00354 |
0.0147 |
0.0147 |
Thyroid cancer |
37 |
14.4 |
23 |
23 |
0.00357 |
0.00357 |
0.0147 |
0.0147 |
Longevity regulating pathway - multiple species |
62 |
24.2 |
35 |
35 |
0.00384 |
0.00384 |
0.0157 |
0.0157 |
Biosynthesis of amino acids |
75 |
29.2 |
41 |
41 |
0.00407 |
0.00407 |
0.0164 |
0.0164 |
Renal cell carcinoma |
69 |
26.9 |
38 |
38 |
0.00472 |
0.00472 |
0.0186 |
0.0186 |
Toll-like receptor signaling pathway |
104 |
40.5 |
54 |
54 |
0.00475 |
0.00475 |
0.0186 |
0.0186 |
Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate |
20 |
7.8 |
14 |
14 |
0.00487 |
0.00487 |
0.0189 |
0.0189 |
Estrogensignaling pathway |
138 |
53.8 |
69 |
69 |
0.00518 |
0.00518 |
0.0198 |
0.0198 |
Terpenoid backbone biosynthesis |
22 |
8.58 |
15 |
15 |
0.00525 |
0.00525 |
0.0199 |
0.0199 |
Glycine, serine and threonine metabolism |
40 |
15.6 |
24 |
24 |
0.00562 |
0.00562 |
0.021 |
0.021 |
Spliceosome |
134 |
52.2 |
67 |
67 |
0.00581 |
0.00581 |
0.0214 |
0.0214 |
Oocyte meiosis |
125 |
48.7 |
63 |
63 |
0.00586 |
0.00586 |
0.0214 |
0.0214 |
VEGF signaling pathway |
59 |
23 |
33 |
33 |
0.00598 |
0.00598 |
0.0216 |
0.0216 |
Adherens junction |
72 |
28.1 |
39 |
39 |
0.00617 |
0.00617 |
0.022 |
0.022 |
Pyrimidine metabolism |
57 |
22.2 |
32 |
32 |
0.00626 |
0.00626 |
0.0221 |
0.0221 |
Proteoglycans in cancer |
201 |
78.4 |
96 |
96 |
0.00636 |
0.00636 |
0.0222 |
0.0222 |
Pathogenic Escherichia coli infection |
55 |
21.4 |
31 |
31 |
0.00654 |
0.00654 |
0.0226 |
0.0226 |
MAPK signaling pathway |
295 |
115 |
136 |
136 |
0.0066 |
0.0066 |
0.0226 |
0.0226 |
Fatty acid metabolism |
53 |
20.7 |
30 |
30 |
0.00683 |
0.00683 |
0.0231 |
0.0231 |
Fc gamma R-mediated phagocytosis |
91 |
35.5 |
47 |
47 |
0.00917 |
0.00917 |
0.0307 |
0.0307 |
N-Glycan biosynthesis |
50 |
19.5 |
28 |
28 |
0.0107 |
0.0107 |
0.0354 |
0.0354 |
Cellular senescence |
160 |
62.4 |
77 |
77 |
0.0109 |
0.0109 |
0.0356 |
0.0356 |
Fatty acid degradation |
44 |
17.2 |
25 |
25 |
0.0122 |
0.0122 |
0.0397 |
0.0397 |
Glycolysis / Gluconeogenesis |
68 |
26.5 |
36 |
36 |
0.0132 |
0.0132 |
0.0419 |
0.0419 |
Fc epsilon RI signaling pathway |
68 |
26.5 |
36 |
36 |
0.0132 |
0.0132 |
0.0419 |
0.0419 |
Alanine, aspartate and glutamate metabolism |
36 |
14 |
21 |
21 |
0.0144 |
0.0144 |
0.0452 |
0.0452 |
Signaling pathways regulating pluripotency of stem cells |
139 |
54.2 |
67 |
67 |
0.016 |
0.016 |
0.0498 |
0.0498 |
2-Oxocarboxylic acid metabolism |
18 |
7.02 |
12 |
12 |
0.0161 |
0.0161 |
0.0498 |
0.0498 |
One carbon pool by folate |
20 |
7.8 |
13 |
13 |
0.0165 |
0.0165 |
0.0505 |
0.0505 |
Pyruvate metabolism |
39 |
15.2 |
22 |
22 |
0.0202 |
0.0202 |
0.0613 |
0.0613 |
Amino sugar and nucleotide sugar metabolism |
48 |
18.7 |
26 |
26 |
0.0231 |
0.0231 |
0.0693 |
0.0693 |
Antifolate resistance |
31 |
12.1 |
18 |
18 |
0.0241 |
0.0241 |
0.0717 |
0.0717 |
GnRHsignaling pathway |
93 |
36.3 |
46 |
46 |
0.0249 |
0.0249 |
0.0734 |
0.0734 |
Wntsignaling pathway |
158 |
61.6 |
74 |
74 |
0.0256 |
0.0256 |
0.0745 |
0.0745 |
Insulin signaling pathway |
137 |
53.4 |
65 |
65 |
0.0258 |
0.0258 |
0.0745 |
0.0745 |
Regulation of lipolysis in adipocytes |
55 |
21.4 |
29 |
29 |
0.0262 |
0.0262 |
0.0751 |
0.0751 |
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis |
25 |
9.75 |
15 |
15 |
0.0268 |
0.0268 |
0.0761 |
0.0761 |
Tryptophan metabolism |
42 |
16.4 |
23 |
23 |
0.0272 |
0.0272 |
0.0766 |
0.0766 |
Protein export |
23 |
8.97 |
14 |
14 |
0.0275 |
0.0275 |
0.0768 |
0.0768 |
Longevity regulating pathway |
89 |
34.7 |
44 |
44 |
0.0281 |
0.0281 |
0.0778 |
0.0778 |
Steroid biosynthesis |
19 |
7.41 |
12 |
12 |
0.0284 |
0.0284 |
0.0778 |
0.0778 |
Sphingolipid signaling pathway |
119 |
46.4 |
57 |
57 |
0.0286 |
0.0286 |
0.0778 |
0.0778 |
Insulin resistance |
108 |
42.1 |
52 |
52 |
0.0319 |
0.0319 |
0.0859 |
0.0859 |
Peroxisome |
83 |
32.4 |
41 |
41 |
0.0337 |
0.0337 |
0.0902 |
0.0902 |
Inositol phosphate metabolism |
74 |
28.8 |
37 |
37 |
0.0345 |
0.0345 |
0.0915 |
0.0915 |